Mineralcorticoid antagonists in heart failure.

Abstract	Mineralocorticoid receptor antagonists (MRAs) have become mandated therapy in patients with reduced ejection fraction (systolic) heart failure (HF) across all symptom classes. These agents should also be prescribed in the early post-myocardial infarction setting in those with reduced ejection fraction and either HF symptoms or diabetes. This article explores the pathophysiological role of aldosterone, an endogenous ligand for the mineralcorticoid receptor (MR), and summarizes the clinical data supporting guideline recommendations for these agents in systolic HF. The use of MRAs in novel areas beyond systolic HF ejection is also explored. Finally, the current status of newer agents will be examined.
Authors	Emilia D'Elia, Henry Krum
Journal	Heart failure clinics (Heart Fail Clin) Vol. 10 Issue 4 Pg. 559-64 (Oct 2014) ISSN: 1551-7136 [Print] United States
PMID	25217431 (Publication Type: Journal Article)
Copyright	Copyright © 2014 Elsevier Inc. All rights reserved.
Chemical References	Mineralocorticoid Receptor Antagonists Aldosterone Canrenone
Topics	Aldosterone (physiology) Canrenone (therapeutic use) Clinical Trials as Topic Heart Failure (drug therapy, etiology) Humans Mineralocorticoid Receptor Antagonists (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!